Article Text

other Versions

PDF
"Non-responders" to Bevacizumab (Avastin™) therapy of choroidal neovascular lesions
  1. Anja Lux (anja.lux{at}gmx.net),
  2. Helene Llacer,
  3. Florian M.A. Heussen,
  4. Antonia M. Joussen (joussena{at}googlemail.com)
  1. Department of Ophthalmology, Heinrich Heine University of Duesseldorf, Germany
  2. Department of Ophthalmology, Heinrich Heine University of Duesseldorf, Germany
  3. Department of Ophthalmology, Heinrich Heine University of Duesseldorf, Germany
  4. Department of Ophthalmology, Heinrich Heine University of Duesseldorf, Germany

    Abstract

    Aims: To determine the characteristics of "non-responders" to intravitreal bevacizumab treatment in choroidal neovascularisation (CNV).

    Methods: Forty-three patients with visual loss due to neovascular age-related macular disease (ARMD) (44 eyes) underwent intravitreal injections of 1.25 mg (0.05 ml) bevacizumab and were followed up every 4 weeks for 2, 3, or 6 months. Reinjection was performed when persistent leakage of the CNV was determined by fluorescein angiography, and retinal oedema was assessed by optical coherence tomography (OCT). Non-responders were defined as those patients having reduced or stable visual acuity at the last follow-up.

    Results: Forty-five per cent of the patients were non-responders. In this group the initial CNV size was significantly larger than in the responders. Initial reading ability was significantly lower in non-responders, but the initial foveal oedema was similar in both groups. Gains in mean visual acuity and reading ability were independent of lesion type. The proportion of non-responders to responders in the different lesion type groups was equally distributed. Only patients with the classic type of CNV seemed to respond better.

    Conclusions: In this study initial reasons for "non-responders" to intravitreal bevacizumab treatment in CNV are given. The efficiency of bevacizumab depends on initial lesion size and initial reading ability, but is independent of the amount of intra- and subretinal fluid. There was no general ineffectiveness of bevacizumab with any particular lesion type.

    • age-related macular degeneration
    • anti-VEGF therapy
    • bevacizumab
    • optical coherence tomography

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles